Anteris Technologies Files 8-K on Equity Sales

Ticker: AVR · Form: 8-K · Filed: Oct 24, 2025 · CIK: 2011514

Sentiment: neutral

Topics: equity-sale, 8-k, disclosure

TL;DR

Anteris Tech filed an 8-K for unregistered equity sales - watch for dilution.

AI Summary

Anteris Technologies Global Corp. filed an 8-K on October 24, 2025, reporting unregistered sales of equity securities and Regulation FD disclosures. The filing details the company's principal executive offices located in Eagan, MN, and its principal executive offices in Toowong, QLD, Australia. The company is incorporated in Delaware and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.

Why It Matters

This filing indicates potential new equity issuance, which could impact share dilution and ownership structure for Anteris Technologies Global Corp.

Risk Assessment

Risk Level: medium — Unregistered sales of equity securities can sometimes signal financial distress or a need for capital, potentially impacting existing shareholders.

Key Numbers

Key Players & Entities

FAQ

What type of equity securities were sold in the unregistered offering?

The filing does not specify the type of equity securities sold in the unregistered offering.

Were these sales made to accredited investors?

The filing mentions 'Unregistered Sales of Equity Securities' but does not explicitly state if they were made to accredited investors.

What is the purpose of these unregistered equity sales?

The filing does not disclose the specific purpose for the unregistered sales of equity securities.

When did the earliest event reported in this 8-K occur?

The earliest event reported in this 8-K occurred on October 23, 2025.

What is Anteris Technologies Global Corp.'s Standard Industrial Classification code?

Anteris Technologies Global Corp.'s SIC code is 3842, for Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 12.7 · Accepted 2025-10-24 17:10:36

Key Financial Figures

Filing Documents

02

Item 3.02. Unregistered Sales of Equity Securities. On or about October 23, 2025 (October 24, 2025 AEST), Anteris Technologies Global Corp. (the "Company") entered into (i) subscription agreements (the "Subscription Agreements") with certain investors, pursuant to which we agreed to sell 2,244,896 shares (the "Shares") of the Company's common stock, par value $0.0001 per share ("Common Stock"), and accompanying five-year warrants (the "Common Stock Warrants") to purchase 2,244,896 shares of Common Stock at a price of US$4.90 per share of Common Stock and accompanying Common Stock Warrant (the "Common Stock Offering"), and (ii) confirmation letters (the "Confirmation Letters") with certain investors, pursuant to which we agreed to sell 2,788,064 CHESS Depositary Interests ("CDIs") and accompanying five-year warrants (the "CDI Warrants") to purchase 2,788,064 CDIs at a price of A$7.50 per CDI and accompanying CDI Warrant (the "CDI Offering", and together with the Common Stock Offering, the "Offering"). The Common Stock Offering is expected to close on or around October 27, 2025, subject to customary closing conditions. The CDI Offering is expected to settle on or around October 30, 2025, subject to customary closing conditions. The Offering is expected to result in aggregate gross proceeds of approximately US$25 million. Evolution Capital Pty Ltd acted as lead manager for the CDI Offering, and will be issued 250,000 CDI Warrants. Each of the Common Stock Warrants and the CDI Warrants are exercisable commencing six months following the date of issuance. The exercise price of the Common Stock Warrants is $7.50 per share, and the exercise price of the CDI Warrants is A$11.50 per CDI. As part of the Subscription Agreements and the Confirmation Letters, the Company is required to prepare and file a registration statement (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Secu

01

Item 7.01. Regulation FD Disclosure. Attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is a form of corporate presentation used by the Company in discussions with certain of its securityholders and other persons. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements, including statements regarding the expected closing dates of the offering, the expected gross proceeds from the offering and the expected cash of the Company following the Offering. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 99.1 Corporate Presentation, dated October 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anteris Technologies Global Corp. Date: October 24, 2025 By: /s/ Wayne Paterson Name: Wayne Paterson Title: Vice Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing